Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associ… Read more
Disc Medicine Inc. (IRON) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.083x
Based on the latest financial reports, Disc Medicine Inc. (IRON) has a cash flow conversion efficiency ratio of -0.083x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-47.80 Million) by net assets ($573.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Disc Medicine Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Disc Medicine Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Disc Medicine Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Disc Medicine Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JB Chemicals & Pharmaceuticals Limited
NSE:JBCHEPHARM
|
0.095x |
|
Photronics Inc
NASDAQ:PLAB
|
0.059x |
|
Joulwatt Technology Co. Ltd. A
SHG:688141
|
-0.026x |
|
Reliance Worldwide Corporation Limited
PINK:RLLWF
|
0.063x |
|
Changzhou Fusion New Material Co. Ltd. A
SHG:688503
|
N/A |
|
Dynex Capital Inc
NYSE:DX
|
0.035x |
|
Aecc Aero Engine Control Co Ltd
SHE:000738
|
-0.025x |
|
BTS Group Holdings Public Company Limited
PINK:BTGWF
|
0.132x |
Annual Cash Flow Conversion Efficiency for Disc Medicine Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Disc Medicine Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $443.59 Million | $-93.93 Million | -0.212x | +0.52% |
| 2023-12-31 | $345.12 Million | $-73.46 Million | -0.213x | +11.03% |
| 2022-12-31 | $176.60 Million | $-42.25 Million | -0.239x | -155.79% |
| 2021-12-31 | $-64.20 Million | $-27.53 Million | 0.429x | -71.34% |
| 2020-12-31 | $-21.86 Million | $-32.71 Million | 1.496x | -- |